Cyclo Therapeutics, Inc.
CYTHDelisted Mar 26, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000922247
Cyclo Therapeutics, Inc. was delisted on Mar 26, 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.
13F holders, Q2 2024
Institutional positions in Cyclo Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- 0 vs. Q1 2024
- Shares held
- 2.24M
- +73.3K (+3.4%) vs. Q1 2024
- Total value
- $2.84M
- −$166.3K (−5.5%) vs. Q1 2024
- New holders
- 1
- 5 more added
- Sold out
- 1
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 22 | $1.33M |
| Q3 2024 | 19 | $1.80M |
| Q2 2024 | 22 | $2.84M |
| Q1 2024 | 22 | $3.01M |
| Q4 2023 | 23 | $2.06M |
| Q3 2023 | 17 | $682.7K |
| Q2 2023 | 14 | $725.2K |
| Q1 2023 | 16 | $820.2K |
| Q4 2022 | 15 | $1.83M |
| Q3 2022 | 12 | $768.0K |
| Q2 2022 | 13 | $794.0K |
| Q1 2022 | 13 | $1.38M |
| Q4 2021 | 15 | $1.71M |
| Q3 2021 | 13 | $2.23M |
| Q2 2021 | 12 | $2.70M |
| Q1 2021 | 9 | $585.0K |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Cyclo Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Qube Research & Technologies Ltd | 21 | $27 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 67 | $85 | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 90 | $114 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 153 | $194 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 210 | $266 | 0.00% | +183+677.8% | Added |
| Royal Bank of Canada | 746 | $1.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,031 | $1.31K | 0.00% | −6−0.6% | Reduced |
| Princeton Global Asset Management LLC | 3,766 | $4.78K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 4,391 | $5.58K | 0.00% | −174−3.8% | Reduced |
| Tower Research Capital LLC (TRC) | 4,999 | $6.35K | 0.00% | −1,583−24.1% | Reduced |
| UBS Group AG | 12,053 | $15.3K | 0.00% | +7,225+149.6% | Added |
| Renaissance Technologies LLC | 13,356 | $17.0K | 0.00% | −8,400−38.6% | Reduced |
| Wealth Enhancement Advisory Services, LLC | 20,400 | $25.9K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 21,722 | $27.6K | 0.00% | −19−0.1% | Reduced |
| Citadel Advisors LLC | 24,670 | $31.3K | 0.00% | +24,670 | New |
| State Street Corp | 39,530 | $50.2K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 59,510 | $75.6K | 0.00% | +22,384+60.3% | Added |
| Founders Fund VI Management, LLC | 110,023 | $139.7K | 100.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 175,418 | $222.8K | 0.00% | +15,669+9.8% | Added |
| Vanguard Group Inc | 446,573 | $567.1K | 0.00% | +49,915+12.6% | Added |
| Founders Fund V Management, LLC | 480,708 | $610.5K | 72.16% | 00.0% | Unchanged |
| EPIQ Capital Group, LLC | 817,270 | $1.04M | 0.37% | −36,545−4.3% | Reduced |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −67−100.0% | Sold out |